The Impact of TSC-1 and -2 Mutations on Response to Therapy in Malignant PEComa: A Multicenter Retrospective Analysis
Lawrence Liu(City of Hope), Angela C. Hirbe(Washington University in St. Louis), John S.A. Chrisinger(The University of Texas MD Anderson Cancer Center), Mia C. Weiss(Washington University in St. Louis), Amanda Parkes(University of Wisconsin–Madison), Dana C. Borcherding(Washington University in St. Louis), Jingqin Luo(Washington University in St. Louis), Yu Tao(Harbin Institute of Technology), Elizabeth J. Davis(Vanderbilt University Medical Center), Varun Monga(University of Iowa), Carina Dehner(Indiana University School of Medicine), Mohammed Milhem(University of Iowa), Xiao Zhang(Ministry of Science and Technology), Yang Lyu(Beijing Institute of Technology), Nam Q. Bui(Stanford University), Nikhil Grandhi(Washington University in St. Louis), Brian A. Van Tine(Washington University in St. Louis)
Cited by 13
Related Papers
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
|New England Journal of Medicine|2021|869
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance)
|Journal of Clinical Oncology|2017|411
Sex differences in cancer mechanisms
|Biology of Sex Differences|2020|377